GlassScriptPhysician profile
Denis Fitzgerald
NPI 1265427223
$21,146.79
in general payments reported to CMS, 2019-2025
22 companies · $308 in 2025
The $308 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,740 · 2020: $11K · 2021: $3,405 · 2022: $65.59 · 2023: $47.95 · 2024: $3,523 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,290 · Food and Beverage: $532 · Education: $56.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,290.00 |
| Food and Beverage | $531.85 |
| Education | $56.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,818.17 | 2020-2024 | |
| Celgene Corporation | $4,076.58 | 2019-2023 | Reblozyl |
| Acceleron Pharma, INC. | $3,960.00 | 2020 | |
| Beigene USA, INC. | $1,967.50 | 2023-2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $1,779.21 | 2021-2025 | Opdualag, Krazati |
| Blueprint Medicines Corporation | $1,480.00 | 2020 | |
| Athenex Pharmaceutical Division, LLC | $1,250.00 | 2020 | |
| Adc Therapeutics America, INC. | $167.74 | 2024 | |
| Gilead Sciences, INC. | $105.24 | 2021-2025 | Trodelvy |
| Comsort, INC | $100.00 | 2019 | |
| Janssen Biotech, INC. | $99.87 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $97.26 | 2025 | Gore Seamguard Bioabsorbable Staple Line Reinforce |
| Intera Oncology, INC | $88.22 | 2025 | Intera |
| Covidien LP | $37.51 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $34.04 | 2024 | Libtayo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $22.50 | 2025 | Enhertu |
| Pfizer INC. | $13.86 | 2020 | |
| Amgen INC. | $13.40 | 2022 | |
| Lilly USA, LLC | $12.58 | 2022 | |
| Genzyme Corporation | $12.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.95 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denis Fitzgerald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.